Rusfertide is a medicine for polycythemia vera, a blood condition where the body makes too many red blood cells. It's given as an injection under the skin. It works by limiting the iron the body uses to make red blood cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Mimrylo (Rusfertide) for Polycythemia Vera?
Rusfertide, sold as Mimrylo, is a prescription injection for adults with polycythemia vera (PV), a chronic blood cancer in which the bone marrow makes too many red blood cells. It was approved in the US in 2026 to treat that excess of red cells, which doctors call erythrocytosis. Extra red cells thicken the blood and raise the risk of clots, so PV care aims to keep the hematocrit (the share of the blood's volume made up of red cells) below 45%. Many people reach that target with phlebotomy, the regular removal of blood, sometimes combined with a medicine that slows the marrow, such as hydroxyurea. The trial that led to approval studied people who still needed blood removed frequently despite that care, and rusfertide was added to their existing treatment rather than replacing it.
Making red blood cells takes a steady supply of iron. The body controls that supply with hepcidin, its main iron-regulating hormone, which works by blocking ferroportin, a transporter that lets iron out of cells and into the blood. Rusfertide is a lab-made peptide that mimics hepcidin. By holding iron back, it limits how much reaches the bone marrow, so the marrow makes fewer red cells and the hematocrit falls. This also changes the iron picture. Phlebotomy controls hematocrit by removing iron along with blood, and many people with PV are already low in iron, which can add to fatigue and poor concentration. With rusfertide, less blood needs to be removed and stored iron tends to recover: in the main trial, average ferritin (a blood test of stored iron) rose several-fold over 32 weeks. That iron is kept in storage rather than used to make extra red cells. Rusfertide works on the iron supply, not on the overactive marrow itself, so it does not lower platelet or white cell counts.
Mimrylo is injected under the skin of the belly, the front of the thigh or, when a caregiver gives it, the outer upper arm, on a weekly schedule. Each dose comes as a powder in a vial that is mixed with the liquid in a supplied prefilled syringe, gently swirled rather than shaken, and used within 4 hours. A clinician shows the patient or caregiver how to prepare and give the injection before treatment starts. Rotating sites and avoiding skin that is tender, bruised or broken helps limit irritation. The cartons are stored at room temperature. Treatment usually starts at 19 mg once a week. Based on blood counts, the dose is raised in steps no sooner than every 2 weeks, or lowered if the blood count drops too far, within a range of 9.5 mg to 108 mg a week. Weekly doses above 54 mg take two injections, and the highest doses are split across two days of the week. Because the dose depends on test results, follow the care team's current instructions, and call them if unsure what to do after a missed injection.
Injection site reactions are the most common side effect. About half of people in the main trial had redness, itching, pain or swelling where they injected, and nearly all were mild or moderate. Ice, a steroid cream, an antihistamine or a pain reliever can help; a reaction that is severe or does not settle is worth reporting to the care team. Because rusfertide restricts the iron used to make red cells, it can push the blood count too low. Anemia affected about 1 in 6 people in the trial and was the usual reason for lowering the dose. About 8% reported shortness of breath, often with exertion. Regular blood counts are how anemia is caught, and new tiredness or breathlessness is worth mentioning. Rusfertide can also raise the platelet count, usually within the first month. Since PV already raises the risk of blood clots, a large rise may lead the care team to lower the dose, stop it, or start or adjust another PV medicine. Contact the care team promptly about unusual bruising or bleeding, or pain or swelling in a leg. Chest pain, sudden severe shortness of breath or a sudden severe headache need emergency care right away, since they can signal a clot in the heart, lungs or brain.
The US prescribing information lists no specific drug interactions and no situations in which rusfertide must never be used. The care team should still know about every other medicine and supplement, since PV treatment often involves several. In animal studies, rusfertide caused birth defects and pregnancy loss at exposures below those used in people, so it may harm a developing baby. For anyone who could become pregnant, a pregnancy test is recommended before starting, along with effective contraception during treatment and for at least 30 days after the last dose. Anyone who becomes pregnant should stop it and tell the care team. Breastfeeding is not advised during treatment or for 30 days afterward, in part because the medicine could interfere with how a baby absorbs iron. Rusfertide is approved only for adults and has not been studied in children.
Rusfertide lowers the hematocrit fairly quickly, but finding the right dose takes time. Expect blood counts every 2 to 4 weeks after starting and whenever the dose changes, with the same goal as phlebotomy: keeping the hematocrit below 45%. In the main trial, which lasted 32 weeks, about 77% of people on rusfertide no longer qualified for phlebotomy during the final 3 months, compared with 33% on a placebo. On average they needed about half a phlebotomy each over the whole period, compared with nearly two on placebo. Fatigue scores improved slightly more than with placebo. Not everyone responds, and some people still need occasional phlebotomy. Rusfertide controls red cell production while it is being taken; it does not cure PV, and other parts of PV care continue alongside it. Whether it reduces clots or changes the long-term course of PV over years has not yet been shown.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Mimrylo (Rusfertide), what you've noticed, or ask the community a question.